EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Treatment (EGFR-TKI Inhibitors, Immunotherapy), By Stages of the Disease (Early-stage NSCLC, Metastatic NSCLC), By Therapy Approvals (First-line Treatments, Second-line Treatments), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).The report offers the value (in USD billion) for the above-mentioned segments.

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Treatment (EGFR-TKI Inhibitors, Immunotherapy), By Stages of the Disease (Early-....

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Size

Market Size in USD

CAGR7.7%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	7.7%
Market Concentration	High
Major Players	AstraZeneca, Janssen Pharmaceuticals, Pfizer, Roche, Novartis

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Analysis

The EGFR non-small cell lung cancer (EGFR + NSCLC) market is estimated to be valued at USD 4.31 Bn in 2024 and is expected to reach USD 7.27 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031. The increasing prevalence of lung cancer across the world and rising focus on targeted therapies to treat NSCLC are fueling the growth of this market.

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Report Snapshots

Buy Now